Donald McLaren

Donald McLaren currently serves as the Director of Clinical Biomarkers & Translation Medicine at Vigil Neuroscience and is the Founder and Principal Consultant at NeuroKirn International, focusing on biomarker and therapeutic development consulting. Previously, Donald held the position of Associate Scientific Director of Biomarkers at Biogen from August 2018 to March 2023 and has contributed as a Clinical Scientist at Biospective Inc., where responsibilities included the development and validation of clinical imaging biomarkers for CNS diseases. Donald has also provided consultancy services to various academic institutions, including the University of Washington and The University of Alabama at Birmingham, while conducting post-doctoral research at Harvard Medical School and Massachusetts General Hospital, concentrating on Alzheimer's disease detection and therapeutic approaches. Donald holds a PhD in Neuroscience from the University of Wisconsin-Madison and an AB in Biology and Neuroscience from the University of Chicago.